Compare Fox Corp Class A (FOXA) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Fox Corp Class A vs State Street SPDR S&P Biotech ETF — how do they compare? Fox Corp Class A trades at $62.43 (market cap $25.36B), while State Street SPDR S&P Biotech ETF trades at $153.81 (market cap $10.11B). The key difference: Fox Corp Class A is far larger — about 2.5× State Street SPDR S&P Biotech ETF's market cap, and Fox Corp Class A pays a 0.91% dividend while State Street SPDR S&P Biotech ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Fox Corp Class A for 34 Days and State Street SPDR S&P Biotech ETF for 38 Days on average.
| FOXA | XBI | |
|---|---|---|
Market Cap | $25.36B | $10.11B |
Volume | 2,566,954 | 12,903,266 |
Sector | Media | Broad Market / Factor |
52-Week High | $76.11 | $169.55 |
52-Week Low | $48.79 | $104.99 |
Typical Hold Time | 34 Days | 38 Days |
Enterprise Value | $28.72B | — |
Dividend Yield | 0.91% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Fox Corporation (FOXA) trades at $62.68, down slightly by 0.03% on the day. The stock shows a bullish technical signal with strong earnings beats in recent quarters, including Q2 2026 EPS of $1.79 versus $1.44 expected. Revenue grew to $16.30 billion in 2025, with a net income margin of 13.88%. Key developments include the pending $22 billion acquisition of Roku, which is under DOJ review, and a dividend payment scheduled for September 2026.
The outlook is positive with a consensus price target of $72.00, implying 15% upside. Strengths include robust cash flow and analyst support, but risks involve regulatory scrutiny of the Roku deal and a projected decline in 2026 net income. The stock presents a value opportunity with a P/E of 16.55, though investors should monitor deal progression and earnings sustainability.
XBI trades at $153.84, up 2.4% today, but technical indicators signal a bearish trend with resistance at $154. The ETF's modified equal-weight structure offers broad biotech exposure, benefiting from M&A activity and positive clinical catalysts, though key financial ratios are unavailable. Recent news highlights sector optimism driven by cancer vaccine breakthroughs and improved capital access.
Outlook is mixed: bullish sentiment from innovation and M&A supports growth potential, but high volatility and expense ratios relative to peers pose risks. Analyst consensus is neutral (100% Hold), suggesting cautious optimism amid technical bearishness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Fox Corp Class A
Fox operates in cable networks and television. Its cable segment includes Fox News, Fox Business, and sports channels, while its TV segment covers the Fox network, 29 local stations (18 Fox-affiliated), and the ad-supported streaming service Tubi. After selling most of its entertainment assets to Disney in 2019, Fox now focuses on live news and sports, primarily within pay-TV. The Murdoch family controls the company.
Read more on FOXA →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
